Skip to main content

Table 5 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS (n = 224)

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D) n % reporting 3L score increase
3L-VAS
 Improved 0.80 0.88 0.08 (0.02 to 0.14) 0.40* 52 44
 No MCID 0.85 0.81 − 0.04 (− 0.10 to 0.01) − 0.19 101 30
 Worsened 0.81 0.79 − 0.02 (− 0.06 to 0.02) − 0.07 71 21
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) N % reporting 5L score increase
5L-VAS
 Improved 0.78 0.84 0.06 (0.01 to 0.10) 0.31* 55 45
 No MCID 0.83 0.81 − 0.03 (− 0.07 to 0.02) − 0.13 98 36
 Worsened 0.80 0.78 − 0.02 (− 0.06 to 0.02) − 0.11 71 28
  1. MCID minimal clinically important change
  2. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
  3. *p < 0.05; **p < 0.01
\